Insiders Buying Tilly's And 2 Other Stocks

Although U.S. stocks closed mixed on Tuesday, there were a few notable insider trades.

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.

General American Investors

• The Trade: General American Investors Company, Inc. GAM President and CEO Jeffrey W Priest acquired a total of 1,000 shares an average price of $42.19. To acquire these shares, it cost around $42,190.
• What’s Happening: The company’s stock gained around 2% over the past six months.
• What General American Investors Does: General American Investors Company Inc is a closed-end, diversified management investment company.

Tilly's

• The Trade: Tilly's, Inc. TLYS 10% owner Pleasant Lake Partners LLC acquired a total of 130,302 shares at an average price of $7.18. To acquire these shares, it cost around $936,186.
• What’s Happening: Tilly's reported a 7.4% decline in sales to $139.7 million for the 2023 nine-week holiday period ended Dec. 30, 2023.
• What Tilly's Does: Tilly's Inc works as a specialty retailer of casual apparel, footwear, and accessories for young men, young women, boys, and girls.

Don’t forget to check out our premarket coverage here

Champions Oncology

• The Trade: Champions Oncology, Inc. CSBR Director Daniel Mendelson bought a total of 1,000 shares at an average price of $6.15. To acquire these shares, it cost around $6,150.
• What’s Happening: Champions Oncology recently posted a loss for the second quarter.
• What Champions Oncology Does: Champions Oncology Inc is a us-based company which is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs.

Check This Out: Markets Turn More Bullish Ahead Of Inflation Data; Fear & Greed Index Remains In 'Greed' Zone